Enhancement of Quality of Work And Life
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Enhancement of Quality of Work And Life," is exploring ways to help people with certain movement disorders—like Parkinson's Disease and ataxia—stay employed and improve their quality of life. The study is looking at a program called the Participatory Workplace Intervention (PWI), which aims to provide personalized support to help individuals balance their work and life better. By focusing on early assistance for those who want to keep working, the trial hopes to show that such support can enhance work participation and overall well-being.
To participate in this trial, individuals must be between 18 and 65 years old, have a confirmed diagnosis of one of the targeted movement disorders, and be working at least 8 hours a week. Participants should also be willing to discuss their work challenges with their employers, although they don't have to disclose their diagnosis. The trial lasts 18 months and involves remote sessions, meaning participants can engage from home. This study is currently recruiting, and it offers a chance to contribute to important research that could help improve work-life balance for many people facing these conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • having a diagnosis Parkinson Disease, cerebellar ataxia, hereditairy spastic paraparesis, or a slowly progressive neuromuscular or mitochondrial disorder, confirmed by the treating physician (e.g. neurologist, rehabilitation physician)
- • aged 18-65 years;
- • being employed for at least 8 hours per week (at baseline). This also includes individuals who have reduced their working hours until reaching this threshold of 8 hours per week. Working time may be distributed across multiple working days;
- • having the intention to continue to work during the study period of 18 months, to prevent inclusion of participants who plan to retire within the 18-month RCT period;
- • being open to talk to the employer or manager about any changes or limitations in work performance (disclosing the diagnosis is not required, by law).
- Exclusion Criteria:
- • individuals who are at the beginning of a sick leave procedure (under the Gatekeeper Improvement Act; Wvp);
- • being fully self-employed. Partial self-employment in addition to paid employment is allowed, on the condition that the paid employment accounts for more than half of the total weekly working hours;
- • having a second employer for over eight hours per week;
- • proficiency in the Dutch language is not sufficient;
- • severe comorbidity or health-related event that will hamper compliance to the protocol, e.g. in case of a severe cognitive impairment, a relatively abrupt transition to a very progressive manifestation of the disease, a planned surgery.
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Gelderland, Netherlands
Patients applied
Trial Officials
Elbrich Postma, PhD
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported